Transdermal nicotine replacement is associated with lower mortality among active smokers admitted with spontaneous subarachnoid hemorrhage

Active smokers comprise 35–55% of patients admitted with acute spontaneous subarachnoid hemorrhage (SAH). Transdermal nicotine replacement is sometimes prescribed to these patients to prevent a withdrawal syndrome, but the safety of exogenous nicotine during the acute period after SAH is unknown.